These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30225669)

  • 1. A retrospective analysis of the periprocedural management of oral anticoagulants in patients undergoing interventional radiology procedures.
    Marsh K; Ahuja T; Raco V; Green D; Sista AK; Papadopoulos J
    J Thromb Thrombolysis; 2018 Nov; 46(4):451-460. PubMed ID: 30225669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
    Jaffer AK; Ahmed M; Brotman DJ; Bragg L; Seshadri N; Qadeer MA; Klein A
    J Thromb Thrombolysis; 2005 Aug; 20(1):11-6. PubMed ID: 16133889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
    Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
    Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of thromboembolism with short-term interruption of warfarin therapy.
    Garcia DA; Regan S; Henault LE; Upadhyay A; Baker J; Othman M; Hylek EM
    Arch Intern Med; 2008 Jan; 168(1):63-9. PubMed ID: 18195197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
    Badreldin H
    J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures.
    Talukdar A; Wang SK; Czosnowski L; Mokraoui N; Gupta A; Fajardo A; Dalsing M; Motaganahalli R
    J Vasc Surg; 2017 Oct; 66(4):1143-1148. PubMed ID: 28712814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.
    Stanton BE; Barasch NS; Tellor KB
    Pharmacotherapy; 2017 Apr; 37(4):412-419. PubMed ID: 28117916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.